ArticleStem cell research & therapy2017
Compared to the amniotic membrane, Wharton's jelly may be a more suitable source of mesenchymal stem cells for cardiovascular tissue engineering and clinical regeneration.
Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Donor age and sex program MSC secretome signaling: a quadrant framework for precision therapy.Stem cell research & therapy · 2026Article
- Ontogenetic stage and type of donor cells shape extracellular vesicles' therapeutic potential for osteoarthritis.Stem cell research & therapy · 2025Article
- Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-generation Myocardial Repair and Regeneration: Mechanisms and Pre-clinical Evidence.Current cardiology reviews · 2025Review
- In vitro and in vivo assessment of a non-animal sourced chitosan scaffold loaded with xeno-free umbilical cord mesenchymal stromal cells cultured under macromolecular crowding conditions.Biomaterials and biosystems · 2024Article
- Deciphering decidual deficiencies in recurrent spontaneous abortion and the therapeutic potential of mesenchymal stem cells at single-cell resolution.Stem cell research & therapy · 2024Article
- Gene Expression Profiles of Human Mesenchymal Stromal Cells Derived from Wharton's Jelly and Amniotic Membrane before and after Osteo-Induction Using NanoString Platform.Current issues in molecular biology · 2022Article
- Preclinical study of human umbilical cord mesenchymal stem cell sheets for the recovery of ischemic heart tissue.Stem cell research & therapy · 2022Article
- Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges.Biomedicines · 2022Review
- A critical review of fibrous polyurethane-based vascular tissue engineering scaffolds.Journal of biological engineering · 2022Review
- Vascular Remodeling of Clinically Used Patches and Decellularized Pericardial Matrices Recellularized with Autologous or Allogeneic Cells in a Porcine Carotid Artery Model.International journal of molecular sciences · 2022Article
- Placental Tissues as Biomaterials in Regenerative Medicine.BioMed research international · 2022Review
- 3D-printed collagen/silk fibroin/secretome derived from bFGF-pretreated HUCMSCs scaffolds enhanced therapeutic ability in canines traumatic brain injury model.Frontiers in bioengineering and biotechnology · 2022Article
- Umbilical cord mesenchymal stromal cells-from bench to bedside.Frontiers in cell and developmental biology · 2022Review
- Novel cell sources for bone regeneration.MedComm · 2021Review
- Peptidome analysis of umbilical cord mesenchymal stem cell (hUC-MSC) conditioned medium from preterm and term infants.Stem cell research & therapy · 2020Article
- Overview of Current Advances in Extrusion Bioprinting for Skin Applications.International journal of molecular sciences · 2020Review
- Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells.Stem cell research & therapy · 2018Article
- Inhibitory effect of oxidative damage on cardiomyocyte differentiation from Wharton's jelly-derived mesenchymal stem cells.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe success of developing cardiovascular tissue engineering (CTE) grafts greatly needs a readily available cell substitute for endothelial and interstitial cells. Perinatal annexes have been proposed as a valuable source of mesenchymal stem cells (MSCs) for tissue engineering and regenerative medicine. The objective of the present study is to evaluate the potential of human Wharton's jelly MSCs (WJ-MSCs) and amniotic membrane MSCs (AM-MSCs) as a seeding cell in CTE and cardiovascular regenerative medicine.
methodsWJ-MSCs/AM-MSCs were isolated and characterized in vitro according to their morphology, proliferation, self-renewal, phenotype, and multipotency. More importantly, the characteristics of hemocompatibility, extracellular matrix deposition, and gene expression and viability of both MSCs were investigated.
resultsFibroblast-like human WJ-MSCs and AM-MSCs were successfully isolated and positively expressed the characteristic markers CD73, CD90, and CD105 but were negative for CD34, CD45, and HLA-DR. Both MSCs shared trilineage differentiation toward the adipogenic, osteogenic, and chondrogenic lineages. The proliferative and self-renewal capacity of WJ-MSCs was significantly higher than that of AM-MSCs (P < 0.001). WJ-MSCs provided comparable properties of antiplatelet adhesion and did not activate the coagulation cascade to endothelial cells. However, aggregated platelets were visualized on the surface of AM-MSCs-derived cell sheets and the intrinsic pathway was activated. Furthermore, WJ-MSCs have superior properties of collagen deposition and higher viability than AM-MSCs during cell sheet formation.
conclusionsThis study highlights that WJ-MSCs could act as a functional substitute of endothelial and interstitial cells, which could serve as an appealing and practical single-cell source for CTE and regenerative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.